Experiment shows amisulpride enhances contraction force in human and mouse atrial tissues, suggesting agonist function at serotonin receptors.
Based on the chemical structure of amisulpride as a benzamide (4-amino-N-[(1-ethyl-2-pyrrolidinyl)-methyl]-5-(ethylsulfonyl)-2-methoxy-benzamide), we hypothesized that like many other benzamides, amisulpride might be an agonist or antagonist at the human cardiac 5-HT 4 serotonin receptor. To test this hypothesis, we utilized isolated atria from transgenic adult mice with cardiac overexpression of the human 5-HT 4 serotonin receptor (5-HT 4 -TG). In the presence of rolipram (100 nM, a phosphodiesterase IV inhibitor), amisulpride (10 µM) raised the force of contraction in isolated left atrial preparations and the beating rate in isolated spontaneously beating right atrial preparations from 5-HT 4 -TG but not from adult wild-type mice. The positive chronotropic effects of amisulpride in right atrial preparations from 5-HT 4 -TG were smaller than those of 1 µM serotonin and were reversed by 1 µM GR125487, an antagonist at the 5-HT 4 serotonin receptor. Amisulpride (10 µM) raised the force of contraction in human right atrial preparations, obtained from patients undergoing cardiac surgery, only in the presence of 100 nM cilostamide, a phosphodiesterase III inhibitor. The positive inotropic effects of amisulpride in human right atrial preparations were reversed by 1 µM GR125487. These data indeed suggest that amisulpride acts as an agonist at the human cardiac serotonin receptor.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: